Financial Performance - Operating revenue for Q1 2023 reached RMB 2,639,665,769.78, representing a 44.15% increase compared to RMB 1,831,254,151.22 in Q1 2022[2] - Net profit attributable to shareholders was RMB 151,603,818.36, up 39.72% from RMB 108,503,552.76 in the same period last year[2] - Basic earnings per share increased to RMB 0.23, a rise of 35.29% from RMB 0.17 in Q1 2022[3] - The total comprehensive income for Q1 2023 was RMB 161,720,238.98, compared to RMB 94,819,997.43 in Q1 2022[5] - The company reported a net profit margin of approximately 5.74% for Q1 2023, compared to 5.92% in Q1 2022[4] Cash Flow and Assets - The net cash flow from operating activities showed a significant decline, amounting to (RMB 183,742,803.27), a decrease of 937.28% compared to (RMB 17,713,946.61) in Q1 2022[2] - Total assets as of March 31, 2023, were RMB 7,976,649,915.84, down 3.49% from RMB 8,265,131,332.13 at the end of 2022[3] Equity and Returns - The return on equity (ROE) increased to 3.59%, up 0.52 percentage points from 3.07% in Q1 2022[3] - The total equity attributable to shareholders increased to RMB 4,323,961,931.78, a growth of 4.79% from RMB 4,126,460,390.95 at the end of 2022[3] Research and Development - Research and development expenses for Q1 2023 were RMB 112,119,587.26, reflecting an increase from RMB 78,758,186.08 in Q1 2022[4] Accounting Policy Changes - The company has implemented changes to its accounting policies effective from January 1, 2023, in accordance with the Ministry of Finance's announcement on November 30, 2022[6] - The changes include the treatment of deferred income tax related to assets and liabilities arising from individual transactions, which are not subject to initial recognition exemptions[6] - The board of directors approved the accounting policy changes during the 11th meeting of the 10th board session on April 20, 2023[6]
山东新华制药股份(00719) - 2023 Q1 - 季度业绩